GlaxoSmithKline Plc has entered a new oncology pact in order to complete a group of assets that target receptors transmitting signals to immune cells. The collaboration is with iTeos Therapeutics of Belgium which was founded in 2011 to explore the tumour microenvironment and immunosuppressive pathways that affect cancer.
